Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP-ACT: Intra-Arterial Treatment of Medium-sized Primary Vessel Occlusions
NCT07906275Phase 3Not yet recruiting
- Sponsor
- University of Calgary
- Start
- Dec 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
A Phase 3 trial of tenecteplase, tissue-plasminogen activator in ischemic stroke, sponsored by University of Calgary. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
tenecteplasetissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07906275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07906275.